{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5"},{"groupId":"OG001","value":"77.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1338"},{"groupId":"OG001","value":"1334"}],"units":"Participants"}],"description":"Where events are defined as recurrence, second primary cancer, or death from any cause","groups":[{"description":"Oxaliplatin + Leucovorin + 5-Fluorouracil","id":"OG000","title":"Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil"},{"description":"Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab","id":"OG001","title":"Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Disease-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of patients"}